search
Back to results

Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery

Primary Purpose

Open Angle Glaucoma

Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Collagen Matrix in Glaucoma Filtering Surgery
Mitomycin-C(MMC) and glaucoma filtering surgery
Sponsored by
Pro Top & Mediking Company Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Open Angle Glaucoma focused on measuring ologen, collagen matrix, glaucoma, trabeculectomy, Mitomycin-C

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Open angle glaucoma
  • Maxima anti-glaucoma medication failed
  • Age>18
  • Able to complete the follow up

Exclusion Criteria:

  • Topical eye inflammation
  • Angle closure glaucoma
  • Deformity glaucoma
  • One eye glaucoma
  • Previous conjunctiva opened
  • Allergy to collagen

Sites / Locations

  • Hospital of Universität Köln

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

MITOMYCIN-C

ologen (Oculusgen)

Arm Description

Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.

20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.

Outcomes

Primary Outcome Measures

Postoperative Intraocular Pressure Change
Postoperative intraocular pressure change at 360 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Postoperative Intraocular Pressure Change
Postoperative intraocular pressure change at 180 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Postoperative Intraocular Pressure Change
Postoperative intraocular pressure change at 90 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Postoperative Intraocular Pressure Change
Postoperative intraocular pressure change at 30 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.

Secondary Outcome Measures

Complications
Incidence (percentage) for complications recorded: Hyphema, early hypotony(<7days), late hypotony(>7days), shallow anterior chamber, choroidal detachment, early leak(<7days), late leak(>7days), Tenon's cysts, and revision surgery for up to 360 days.

Full Information

First Posted
September 29, 2007
Last Updated
April 1, 2012
Sponsor
Pro Top & Mediking Company Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT00538590
Brief Title
Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
Official Title
Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pro Top & Mediking Company Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To compare the safety and effectiveness of oculusgen (ologen) collagen matrix implantation and Mitomycin-C(MMC) in glaucoma surgery.
Detailed Description
To compare the safety and effectiveness in between oculusgen (ologen) collagen matrix implantation and Mitomycin-C(MMC) for glaucoma surgery. The surgery is performed by the gold standard of trabeculectomy. Mitomycin-C(MMC) is applied for those who not collagen matrix implanted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Angle Glaucoma
Keywords
ologen, collagen matrix, glaucoma, trabeculectomy, Mitomycin-C

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MITOMYCIN-C
Arm Type
Active Comparator
Arm Description
Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
Arm Title
ologen (Oculusgen)
Arm Type
Experimental
Arm Description
20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
Intervention Type
Device
Intervention Name(s)
Collagen Matrix in Glaucoma Filtering Surgery
Other Intervention Name(s)
ologen™
Intervention Description
Collagen Matrix implantation in Glaucoma Filtering Surgery
Intervention Type
Drug
Intervention Name(s)
Mitomycin-C(MMC) and glaucoma filtering surgery
Other Intervention Name(s)
Mitomycin C
Intervention Description
If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
Primary Outcome Measure Information:
Title
Postoperative Intraocular Pressure Change
Description
Postoperative intraocular pressure change at 360 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Time Frame
360 days
Title
Postoperative Intraocular Pressure Change
Description
Postoperative intraocular pressure change at 180 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Time Frame
180 days
Title
Postoperative Intraocular Pressure Change
Description
Postoperative intraocular pressure change at 90 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Time Frame
90 days
Title
Postoperative Intraocular Pressure Change
Description
Postoperative intraocular pressure change at 30 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Complications
Description
Incidence (percentage) for complications recorded: Hyphema, early hypotony(<7days), late hypotony(>7days), shallow anterior chamber, choroidal detachment, early leak(<7days), late leak(>7days), Tenon's cysts, and revision surgery for up to 360 days.
Time Frame
360 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Open angle glaucoma Maxima anti-glaucoma medication failed Age>18 Able to complete the follow up Exclusion Criteria: Topical eye inflammation Angle closure glaucoma Deformity glaucoma One eye glaucoma Previous conjunctiva opened Allergy to collagen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Dietlein, Ph. D, MD
Organizational Affiliation
Universität Köln
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital of Universität Köln
City
Koln
ZIP/Postal Code
50931
Country
Germany

12. IPD Sharing Statement

Links:
URL
http://www.nature.com/eye/journal/v24/n9/pdf/eye2010106a.pdf
Description
Publication on Eye

Learn more about this trial

Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery

We'll reach out to this number within 24 hrs